𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Worsening of levodopa-induced dyskinesias by motor and mental tasks

✍ Scribed by Franck Durif; Marie Vidailhet; Bérangère Debilly; Yves Agid

Publisher
John Wiley and Sons
Year
1999
Tongue
English
Weight
31 KB
Volume
14
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Automatic assessment of levodopa-induced
Automatic assessment of levodopa-induced dyskinesias in daily life by neural networks
✍ Noël L.W. Keijsers; Martin W.I.M. Horstink; Stan C.A.M. Gielen 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 208 KB

## Abstract We developed an objective and automatic procedure to assess the severity of levodopa‐induced dyskinesia (LID) in patients with Parkinson's disease during daily life activities. Thirteen patients were continuously monitored in a home‐like situation for a period of approximately 2.5 hours

Prevention of levodopa-induced dyskinesi
Prevention of levodopa-induced dyskinesias by a selective NR1A/2B N-methyl-D-aspartate receptor antagonist in parkinsonian monkeys: Implication of preproenkephalin
✍ Marc Morissette; Mehdi Dridi; Frédéric Calon; Abdallah Hadj Tahar; Leonard T. Me 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 175 KB

## Abstract Enkephalin is reported to play an important role in the pathophysiology of levodopa (LD) ‐induced dyskinesias. The present study investigated the effect of chronic treatment with a selective NR1A/2B __N__‐methyl‐D‐aspartate (NMDA) receptor antagonist, CI‐1041, on the expression of prepr

Neural mechanisms underlying peak-dose d
Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct: Evidence from the effects of the alpha2 adrenoceptor antagonist idazoxan
✍ Susan H. Fox; Brian Henry; Micheal P. Hill; David Peggs; Alan R. Crossman; Jonat 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 102 KB

## Abstract Dyskinesia, secondary to dopamine replacement therapy, is the major complication of currently available therapies for Parkinson's disease. Alpha~2~ adrenoceptor antagonists, such as idazoxan, can significantly reduce levodopa‐induced dyskinesia in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydr